Cargando…

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

INTRODUCTION: Early rheumatoid arthritis (RA) patients may show rapid radiographic progression (RRP) despite rapid initiation of synthetic disease-modifying anti-rheumatic drugs (DMARDs). The present study aimed to develop a matrix to predict risk of RRP despite early DMARD initiation in real life s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fautrel, Bruno, Granger, Benjamin, Combe, Bernard, Saraux, Alain, Guillemin, Francis, Le Loet, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674616/ https://www.ncbi.nlm.nih.gov/pubmed/23164197 http://dx.doi.org/10.1186/ar4092

Ejemplares similares

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort
por: Mouterde, Gaël, et al.
Publicado: (2019)

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort
por: Chevreul, Karine, et al.
Publicado: (2014)

Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR)
por: Gandjbakhch, Frederique, et al.
Publicado: (2017)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
por: de Bandt, Michel, et al.
Publicado: (2009)

Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
por: Zhang, Bin, et al.
Publicado: (2012)

Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis
por: Shashikumar, N.S., et al.
Publicado: (2010)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
por: Narváez, Javier, et al.
Publicado: (2015)

Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis
por: Chen, Fang, et al.
Publicado: (2022)

Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
por: Seror, Raphaèle, et al.
Publicado: (2016)

Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate
por: Lee, Sang-Won, et al.
Publicado: (2012)

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2009)

Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort
por: Meyer, Magali, et al.
Publicado: (2013)

Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort
por: Guellec, Dewi, et al.
Publicado: (2015)

Diagnostic impact of routine Lyme serology in recent-onset arthritis: results from the ESPOIR cohort
por: Guellec, Dewi, et al.
Publicado: (2016)

Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
por: Fautrel, B, et al.
Publicado: (2015)

Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort
por: Audo, Rachel, et al.
Publicado: (2015)

Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply
por: Sellam, Jérémie, et al.
Publicado: (2014)

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
por: Gherghe, Ana Maria, et al.
Publicado: (2015)

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort
por: Soubrier, M, et al.
Publicado: (2011)

Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis
por: Duquesne, Julien, et al.
Publicado: (2022)

IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide
por: Zhong, Wei, et al.
Publicado: (2017)

Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis
por: Huang, Yao, et al.
Publicado: (2019)

Serum Fatty Acid Profiles Are Associated with Disease Activity in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
por: Sigaux, Johanna, et al.
Publicado: (2022)

Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
por: Jones, Peter BB, et al.
Publicado: (2010)

Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis
por: Qi, Weiyu, et al.
Publicado: (2021)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’– authors’ reply
por: Toussirot, Eric, et al.
Publicado: (2014)

Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination
por: Vittecoq, Olivier, et al.
Publicado: (2022)

Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial
por: Wang, Zhang, et al.
Publicado: (2020)

The Effect of Leflunomide on Cold and Vibratory Sensation in Patients with Rheumatoid Arthritis
por: Kim, Hyung Kuk, et al.
Publicado: (2012)

Leflunomide-induced and paraneoplastic ulcers in a rheumatoid arthritis patient
por: Vittori, Michael R., et al.
Publicado: (2022)

Differential effects of leflunomide and methotrexate on cytokine production in RA
por: Kraan, MC, et al.
Publicado: (2003)

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients
por: Hopkins, AM, et al.
Publicado: (2015)

Interleukin-18 in Brazilian Rheumatoid Arthritis Patients: Can Leflunomide Reduce It?
por: Gualberto Cardoso, Pablo Ramon, et al.
Publicado: (2021)

Espoir pour l’homéopathie française
por: Sarembaud, Alain
Publicado: (2021)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t4fm5t6qkr052jhr02ke80urpc